内容概要：硬脑（脊）膜补片是指用于硬脑膜和/或硬脊膜缺损暂时或永久性修补的片状材料类产品。 近几年来，随着人口老龄化程度的加深、脑血管疾病发病率的攀升、国民疾病认知水平提升，我国颅脑 肿瘤、颅脑创伤、脑出血等脑部疾病外科手术治疗选择率不断上升，带动硬脑（脊）膜补片应用需求持 续增加，行业规模再度进入增长通道。数据显示，2024年我国硬脑（脊）膜补片市场规模达到11.8亿 元，预计2029年将达到18.41亿元。 相关上市企业：冠昊生物（300238）；正海生物（300653）；迈普医学（301033）；佰仁医疗 （688198）等 相关企业：天新福（北京）医疗器材股份有限公司；深圳市沃尔德外科医疗器械技术有限公司；苏州希 普生物科技有限公司；北京桀亚莱福生物技术有限责任公司；重庆润泽医药有限公司；江西光至金辉医 疗制品有限公司；上海白衣缘生物工程有限公司；陕西佰傲再生医学有限公司等 关键词：产业链；硬脑（脊）膜补片行业规模；竞争格局；重点企业；发展趋势 一、行业概况 硬脑（脊）膜介于颅骨和脑组织之间，具有保护大脑、防止脑脊液漏出的作用，硬脑（脊）膜损伤会导 致脑脊液持续性漏出，进而引发脑膜炎、颅内感染等问题， ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2025005 | 投资者关系活 | ☑特定对象调研 □分析师会议□媒体采访 | | | --- | --- | --- | | 动类别 | □业绩说明会□新闻发布会□路演活动 | | | | ☑现场参观□一对一沟通□其他： | | | 参与单位名称 | | | | | 华创证券 李婵娟；国盛证券 杨芳；中邮证券 陈峻；中信 建投 喻胜锋；广发证券 杨正；国泰基金 邱晓旭；前海鑫 | | | 时间 | | 2025年07月03日 10:30-12:00 | | 地点 | 公司展厅及会议室 | | | 上市公司接待 | 董事、副总经理、财务总监 骆雅红 | | | 人员 | 董事、副总经理、董事会秘书 龙小燕 | | | | 证券事务代表 李晓香 | | | 投资者关系活 | 一、公司基本情况 | | | 动主要内容介 | 公司是一家专注于高性能植入医疗器械的科技创新型 | | | 绍 | 企业，是国内神经外科领域唯一同时拥有人工硬脑（脊） | | | | 东正圆投资 钟晓琳；太平养老 张翼；隆象资本 贺艳 ...

Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

Core Viewpoint - The announcement details the planned share reduction by GuoShou ChengDa, a pre-IPO shareholder of Guangzhou MaiPu Medical Technology Co., Ltd, indicating a reduction of up to 1,995,582 shares, which represents 3% of the company's total share capital [2][3][4]. Group 1: Shareholder Information - GuoShou ChengDa holds 3,267,436 shares, accounting for 4.9120% of the total share capital, and 4.9382% when excluding shares held in the company's repurchase account [2][4]. - The shares held by GuoShou ChengDa were acquired prior to the company's initial public offering and were released from lock-up on July 26, 2022 [3][4]. Group 2: Reduction Plan Details - The reason for the share reduction is stated as operational needs [4]. - The planned reduction includes a maximum of 1,995,582 shares, with 1,330,388 shares to be sold through block trading and the remainder through centralized bidding [3][4]. - The reduction period will commence 15 trading days after the announcement and will last for three months, subject to market conditions [4][6]. Group 3: Compliance and Commitments - GuoShou ChengDa has committed to adhere to legal regulations and the company's internal policies regarding shareholding and reduction [6][7]. - The shareholder has not violated any commitments made during the IPO process and will ensure compliance with all relevant laws during the reduction period [7][8].

预披露公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-040 广州迈普再生医学科技股份有限公司 关于公司首发前股东减持股份的预披露公告 公司首发前股东国寿成达（上海）健康产业股权投资中心（有限合伙）保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、截至本公告披露日，国寿成达（上海）健康产业股权投资中心（有限合 伙）（以下简称"国寿成达"或"本企业"）持有广州迈普再生医学科技股份有 限公司（以下简称"公司"）3,267,436 股，占公司总股本的 4.9120%（占剔除 公司回购专用账户股份数量后总股本的 4.9382%）。 2、国寿成达系 2016 年 12 月在中国证券投资基金业协会完成备案的私募基 金，基金编号为 SN4372。 3、国寿成达因自身经营需要，计划通过集中竞价交易及大宗交易方式合计 减持公司股份不超过 1,995,582 股，占公司总股本的 3.0000%（占剔除公司回购 专用账户股份数量后总股本的 3.0160%）。其中，通过集中竞价方式减持不超过 ...

迈普医学(301033.SZ)公告称，公司首发前股东国寿成达计划通过集中竞价交易及大宗交易方式合计减 持公司股份不超过1,995,582股，占公司总股本的3.0000%（占剔除公司 回购专用账户股份数量后总股本 的3.0160%）。 ...

深耕神外赛道，脑膜胶和可吸收止血纱新品上量可期 [Table_CoverStock] —迈普医学(301033)公司深度报告 [Table_ReportDate] 2025 年 6 月 16 日 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 [Table_StockAndRank] 迈普医学(301033) [Table_CoverAuthor] 唐爱金 医药行业首席分析师 曹佳琳 医药行业分析师 S1500523080002 S1500523080011 tangaijin@cindasc.com caojialin@cindasc.com [Table_CoverReportList] 相关研究 1.集采助力产品放量，盈利能力逐步增强 2.集采压力期已过，国内海外双丰收 投资评级 买入 上次评级 [Table_BaseData] 公司主要数据 | [Table_Profit] 重要财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | ...

Core Viewpoint - The acquisition of Easy Medical Technology by Maipu Medical has raised concerns due to the target company's significant losses and the potential for conflicts of interest, as both companies are controlled by the same individual [2][4][6]. Company Overview - Maipu Medical is a high-tech enterprise focused on developing high-performance implantable medical devices, particularly in the field of neurosurgery [3]. - Easy Medical Technology specializes in providing minimally invasive solutions for cerebrovascular diseases, with products including neuro-interventional catheters and thrombectomy devices [3]. Financial Performance - Easy Medical is projected to incur cumulative net losses exceeding 55 million yuan in 2023 and 2024, while Maipu Medical reported a net profit of 78.85 million yuan in the previous year [2][3]. - In 2023, Easy Medical's revenue was approximately 11.94 million yuan, with a net loss of about 29.51 million yuan, and in 2024, revenue is expected to reach 24.41 million yuan with a net loss of 26.16 million yuan [3]. Acquisition Details - The acquisition aims to expand Maipu Medical's product offerings in the neurosurgery field and integrate channel resources [3][4]. - The transaction involves issuing shares and cash to acquire 100% of Easy Medical, with additional funds raised from the actual controller for transaction-related costs [2]. Concerns and Risks - The transaction has been criticized for its lack of transparency regarding the valuation of Easy Medical, as the board approved the acquisition without a completed audit or assessment [4][6]. - There are concerns about potential conflicts of interest due to the intertwined ownership structures of the companies involved, leading to accusations of a "left hand to right hand" transaction [4][6]. Market Reaction - Following the announcement of the acquisition, Maipu Medical's stock price fell nearly 12% on the first trading day after resuming trading, reflecting investor skepticism about the fairness of the transaction [2][6]. Strategic Rationale - The acquisition is seen as a strategic move to tap into the growing neurovascular intervention market, which is projected to reach 43.2 billion yuan by 2028, with a compound annual growth rate of 36.5% [9][10]. - Maipu Medical aims to leverage its expertise in synthetic materials to develop innovative medical devices in the interventional field, potentially creating a comprehensive solution platform for neurosurgery [7][10].

广州迈普再生医学科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于非独立董事辞任的情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）收到 公司非独立董事郑海莹女士的书面辞任报告。因个人原因，郑海莹女 士申请辞去公司第三届董事会非独立董事职务，辞任后亦不担任公司 相关职务。郑海莹女士原定的任职期间为至第三届董事会任期届满之 日，其辞任不会导致公司董事会人数低于法定最低人数，其辞任报告 自送达公司之日起生效，辞职后不在公司及子公司担任任何职务。郑 海莹女士将按照公司相关规定做好离任交接工作。 董事辞任暨选举职工董事的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-039 董事辞任暨选举职工董事的公告 大会民主选举，选举林洁芬女士（简历详见附件）担任公司第三届董 事会职工董事，任期至第三届董事会任期届满之日。 林洁芬女士符合《公司法》《公司章程》规定的有关职工董事任 职资格和条件。林洁芬女士当选公司职工董事后，公司第三届董事会 中兼任公司高级管理人员职务的董事以及由职工代表担 ...

股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-038 广州迈普再生医学科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日下午 14:30 以现场表决和网络投票相结合的方式召 开公司 2025 年第一次临时股东大会。 1、会议召开时间：2025 年 6 月 13 日（星期五）下午 14:30 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会 议室 3、会议召开方式：采取现场表决与网络投票相结合的方式。现 场会议召开时间：2025 年 6 月 13 日（星期五）。网络投票时间：通 过深圳证券交易所交易系统进行网络投票的时间为：2025 年 6 月 13 日（星期五）上午 9:15-9:25，9:30-11:30 和下午 13 ...